Imaging and Therapy in One Drug
Bone metastases are common, painful, and difficult to treat with conventional intratumoral approaches given the mineralized matrix surrounding tumor cells.
Building on our self-nanotechnology platform, this program is developing a dual-function compound that combines diagnostic imaging capability with cytotoxic and immune-activating therapy in a single agent — allowing clinicians to visualize and treat bone lesions with one intervention.
This complements our broader organ-targeted therapy portfolio, which has already demonstrated durable disappearance of bone metastases in prostate cancer patients treated with our slow-release depot platform.
